Interview with Fangchen Lee, Chairman, Yung Shin Group
Yung Shin has a very long and well-regarded history here in Taiwan. Perhaps we could start by you telling our readers about the recent history of the company and its…
Address: 1191, Sec. 1, Chung Shan Rd. Tachia, Taichung, Taiwan 43744, Republic Of China
Tel: +886-4-2687-5100
For years Yung Shin has been upholding the philosophy of service, honest and innovation and today is a comprehensive international pharmaceutical and healthcare group. Yung Shin has always insisted on its corporate belief that ‘a company improves people’s health by providing the best pharmaceuticals,’ and has treated customer satisfaction as its priority. In the future, Yung Shin will focus on taking the quality of its products to a higher level, and deepen its international competitiveness and global marketing with the foundations it has built overseas over the past years, in order to reach its goal of becoming a dedicated global entity.
Future expansion plans include expanding the company’s business territories with dedicated technologies, and aim to reach the world from the company’s base in Taiwan.
Yung Shin has a very long and well-regarded history here in Taiwan. Perhaps we could start by you telling our readers about the recent history of the company and its…
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s biotech industry, emphasizing the need for risk tolerance and understanding investing rationale in propelling Taiwan’s industry…
Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent…
Dr Yu-Ray Chen, Professor of Surgery at Chang Gung Memorial Hospital discusses the current state of Taiwan’s healthcare system, highlighting the fact that its current condition is unsustainable in the…
James Wang, Country Managing Partner of Ernst & Young Taiwan explains why Taiwan’s DIG (Diversify-Innovative-Globalize) strategy is crucial for the growth of Taiwan’s economy over the next decade, why biotech…
Michael Chiang, the Executive President of Panion & BF Biotech speaks about the incredible growth of the company over the past year, what has contributed to this success and where…
Full service CRO Choice Pharma moved its operations from Europe to Asia in 2008, and since then the company has thrived. The managing director and business director for the company…
A 2006 article in CommonWealth Magazine detailing the genesis of this company reported that TLC had managed to “break out from the typical dilemma of ordinary biotech firms—to either engage…
The president of Pharmaceutical Industry Technology and Development Center (PITDC) considers the company’s need to remain an international competitor and how to achieve it, the gap in new drug development…
General Manager, Chugai Pharma Taiwan and President of International Research-Based Pharmaceutical Manufacturers’ Association (IRPMA), discusses the continuous price cuts that plague the Taiwan market, and how IRPMA is getting involved…
The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the…
The chairman of Taipei Medical University (TMU) discusses the key challenges TMU has faced over the years, how these challenges will continue to affect the future, and what international accreditation…
See our Cookie Privacy Policy Here
